Author

Klimack WK

May 24, 2012
Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas
Summary Background Globally, hepatitis C virus (HCV) infects ~3% of the population. The objective of this study was to review published work and determine the direct medical costs for diseases associated with HCV infection globally, with the exception of the US. Methods A systematic literature search was conducted to identify studies reporting the costs of […]

Read More
December 18, 2011
Economic burden of hepatitis C-associated diseases in the United States
Summary There are approximately 100 drugs in development to treat hepatitis C. Over the next decade, a number of new therapies will become available. A good understanding of the cost of hepatitis C sequelae is important for assessing the value of new treatments. The objective of this study was to assess the economic burden data […]

Read More